Prognostic significance of stem cell markers: In triple-negative breast cancers
World Journal of Clinical Oncology · 27.04.2026
DOI: 10.5306/wjco.119673 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Clinical Oncology, online erschienen am 27.04.2026. Verfasst von Sunil V Jagtap und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is defined by the lack of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2. Investigating the role of cancer stem cell (CSC) markers in TNBC carcinogenesis and tumor progression is of increasing interest. TNBC cells have been reported to exhibit CSC characteristics at functional, molecular, and transcriptional levels. Several stemness markers have been described across different histological subtypes of breast cancer, including CD44, CD24, CD133, EpCAM, CD166, Lgr5, CD47, ALDH1, and ABCG2. Recent studies have demonstrated that CD133 positivity enables the identification of CSC populations in breast cancer. These markers may have enhanced prognostic value if TNBC tumors are further stratified into molecular subtypes, particularly through evaluation of their expression in the mesenchymal stem-like subtype. In this article, we comment on the article by Depar et al published in the World Journal of Clinical Oncology .
Zitieren
APA
Jagtap, S. V., & Jagtap, S. S. (2026). Prognostic significance of stem cell markers: In triple-negative breast cancers. World Journal of Clinical Oncology. https://doi.org/10.5306/wjco.119673
Vancouver
Jagtap SV, Jagtap SS. Prognostic significance of stem cell markers: In triple-negative breast cancers. World Journal of Clinical Oncology. 2026. doi:10.5306/wjco.119673
BibTeX
@article{Jagtap2026,
author = {Jagtap, Sunil V and Jagtap, Shubham S},
title = {Prognostic significance of stem cell markers: In triple-negative breast cancers},
journal = {World Journal of Clinical Oncology},
year = {2026},
doi = {10.5306/wjco.119673}
}
EUVIMED